MedTrace Logo

Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer

NCT00077402 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-05-15

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well fenretinide works in treating patients with advanced or metastatic hormone-refractory prostate cancer.

Conditions

Interventions

DRUG

fenretinide

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Cancer Therapeutics Research Group

    lead OTHER

Principal Investigators

  • Michael Boyer · Sydney Cancer Centre at Royal Prince Alfred Hospital

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2011-01-31
Completion
2011-02-28

Countries

  • Australia
  • Hong Kong
  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00077402 on ClinicalTrials.gov